Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective US chart review.

被引：0
|
作者：
Yang, Hongbo
Wong, Michael K. K.
Signorovitch, James E.
Wang, Xufang
Liu, Zhimei
Liu, Nathan S.
Qi, Zhengyun
George, Daniel J.
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[3] Novartis Pharmaceut, Florham Pk, NJ USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4612
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis
    Zahra Goudarzi
    Mehrdad Mostafavi
    Mahmood Salesi
    Mojtaba Jafari
    Iman Mirian
    Amir Hashemi Meshkini
    Khosro Keshavarz
    Younes Ghasemi
    [J]. Cost Effectiveness and Resource Allocation, 21
  • [42] One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival
    Ito, Hiroki
    Kondo, Keiichi
    Kawahara, Takashi
    Kaneta, Tomohiro
    Tateishi, Ukihide
    Ueno, Daiki
    Namura, Kazuhiro
    Kobayashi, Kazuki
    Miyoshi, Yasuhide
    Yumura, Yasushi
    Makiyama, Kazuhide
    Hayashi, Narihiko
    Hasumi, Hisashi
    Osaka, Kimito
    Yokomizo, Yumiko
    Teranishi, Jun-ichi
    Hattori, Yusuke
    Inoue, Tomio
    Uemura, Hiroji
    Yao, Masahiro
    Nakaigawa, Noboru
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 855 - 861
  • [43] One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival
    Hiroki Ito
    Keiichi Kondo
    Takashi Kawahara
    Tomohiro Kaneta
    Ukihide Tateishi
    Daiki Ueno
    Kazuhiro Namura
    Kazuki Kobayashi
    Yasuhide Miyoshi
    Yasushi Yumura
    Kazuhide Makiyama
    Narihiko Hayashi
    Hisashi Hasumi
    Kimito Osaka
    Yumiko Yokomizo
    Jun-ichi Teranishi
    Yusuke Hattori
    Tomio Inoue
    Hiroji Uemura
    Masahiro Yao
    Noboru Nakaigawa
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 79 : 855 - 861
  • [44] A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy
    Kim, Sung Han
    Suh, Yoon Seok
    Lee, Dong-Eun
    Park, Boram
    Joo, Jungnam
    Joung, Jae Young
    Seo, Ho Kyung
    Lee, Kang Hyun
    Chung, Jinsoo
    [J]. ONCOTARGET, 2017, 8 (55) : 93633 - 93643
  • [45] High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
    Drljevic-Nielsen, A.
    Rasmussen, F.
    Mains, J. R.
    Thorup, K.
    Donskov, F.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [46] Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
    Flaherty, Keith T.
    Rosen, Mark A.
    Heitjan, Daniel F.
    Gallagher, Maryann L.
    Schwartz, Brian
    Schnall, Mitchell D.
    O'Dwyer, Peter J.
    [J]. CANCER BIOLOGY & THERAPY, 2008, 7 (04) : 496 - 501
  • [47] Validation of Serum Amyloid α as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients
    Vermaat, Joost S.
    Gerritse, Frank L.
    van der Veldt, Astrid A.
    Roessingh, Wijnand M.
    Niers, Tatjana M.
    Oosting, Sjoukje F.
    Sleijfer, Stefan
    Roodhart, Jeanine M.
    Beijnen, Jos H.
    Schellens, Jan H.
    Gietema, Jourik A.
    Boven, Epie
    Richel, Dick J.
    Haanen, John B.
    Voest, Emile E.
    [J]. EUROPEAN UROLOGY, 2012, 62 (04) : 685 - 695
  • [48] Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
    Keizman, Daniel
    Gottfried, Maya
    Ish-Shalom, Maya
    Maimon, Natalie
    Peer, Avivit
    Neumann, Avivit
    Hammers, Hans
    Eisenberger, Mario A.
    Sinibaldi, Victoria
    Pili, Roberto
    Hayat, Henry
    Kovel, Svetlana
    Sella, Avishay
    Boursi, Ben
    Weitzen, Rony
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Carducci, Michael A.
    [J]. ONCOLOGIST, 2014, 19 (01): : 51 - 60
  • [49] Can patient-reported kidney cancer specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma?
    Trask, P. C.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Tarazi, J. C.
    Rosbrook, B.
    Bycott, P. W.
    Kim, S.
    Stadler, W. M.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
    Jakub Kucharz
    Agnieszka Giza
    Paulina Dumnicka
    Marek Kuzniewski
    Beata Kusnierz-Cabala
    Pawel Bryniarski
    Roma Herman
    Aneta Lidia Zygulska
    Krzysztof Krzemieniecki
    [J]. Medical Oncology, 2016, 33
12345